Abstract: Disclosed are methods for treating an autoimmune and/or complement mediated disease or condition in a subject. The methods include administering to the subject a compound which inhibits the subject's classical complement pathway. The methods include administering to the subject a compound which inhibits the subject's classical complement pathway. Compositions which include inhibitors of C1q, C1r, C1s, C2 or C4 and a pharmaceutically acceptable excipient are also described.
Abstract: Methods and compositions related to the use of Human proIslet Peptide Receptor (HIP) are disclosed herein. Compositions include peptides and peptidomimetics capable of binding the HIP receptors. Methods include screening assays for ligands of receptors and proteins involved in islet cell signaling.
Abstract: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.
Abstract: Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in modulating intracellular calcium.
Type:
Application
Filed:
September 1, 2010
Publication date:
March 24, 2011
Applicant:
CALCIMEDICA, INC.
Inventors:
Jack Roos, Kenneth A. Stauderman, Gonul Velicelebi, Paul J. Digregorio, Kari Lynn Ohlsen
Abstract: The present invention relates to a peptide for the treatment or prophylaxis of an autoimmune disease, a nucleic acid molecule coding for said peptide, a pharmaceutical composition comprising the peptide and/or the nucleic acid molecule, and to a method for the treatment and/or prophylaxis of an autoimmune disease.
Type:
Application
Filed:
December 3, 2008
Publication date:
March 3, 2011
Inventors:
Robert Weissert, Karl-Heinz Wiesmueller, Katrien L. De Graaf
Abstract: The present invention concerns a peptide molecule or a nucleic acid molecule, for use in medicine and, in particular, for use in preventing or treating a non-cancerous condition or relieving pain in a patient. The invention also relates to a pharmaceutical composition comprising the peptide or nucleic acid molecule of the invention and methods of treatment thereof.
Type:
Application
Filed:
February 25, 2009
Publication date:
March 3, 2011
Applicant:
Helperby Therapeutics Limited
Inventors:
Anthony Robert Milnes Coates, Yanira Riffo-Vasquez, Peter Tormay
Abstract: Disclosed are method for treating diabetes, a protein for treatment of diabetes, and pharmaceutical composition comprising the same. The protein is human mature chemerin, which can be used to treat diabetes, in particular type 2 diabetes, inter alia to treat diabetes in a patient who is concurrently administered with insulin.
Abstract: The object of the present invention is analogues of peptides or parent proteins, these peptide analogues, comprising at least one aza-?3 aminoacyl residue, and also their uses in pharmaceutical compositions or for the diagnosis of pathologies wherein the aforesaid peptides or parent proteins are involved.
Abstract: The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.
Type:
Application
Filed:
April 26, 2010
Publication date:
February 24, 2011
Applicant:
THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Inventors:
Vijay K. Kuchroo, Sumone Chakravarti, Terry Strom, Xin Xiao Zheng, Jennifer Hartt Meyers
Abstract: It is disclosed a method of immunomodulating an immune response in a subject comprising administering to a subject a malleable protein matrix (MPM), from fermented whey, in an amount effective to modulate the biological activity of Th17 cells, and its associated metabolic pathway, for a preventative or a therapeutic purpose of a variety of health applications in the field of immunity or obesity related diseases.
Type:
Application
Filed:
October 2, 2008
Publication date:
January 6, 2011
Applicant:
INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Josee Beaulieu, Jean-Francois Lapointe, Claude Dupont, Pierre Lemieux, Eric Simard, Eric Trottier
Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
Type:
Application
Filed:
May 5, 2010
Publication date:
January 6, 2011
Applicant:
DEVELOGEN AKTIENGESELLSCHAFT
Inventors:
Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
Abstract: In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes.
Type:
Application
Filed:
September 30, 2008
Publication date:
December 23, 2010
Inventors:
Mark A Atkinson, Scott Eisenbeis, Donna Armentano, Abraham Scaria, Tracey Lodie
Abstract: The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions.
Type:
Application
Filed:
June 8, 2010
Publication date:
December 23, 2010
Applicant:
AMUNIX, INC.
Inventors:
Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Willem P. Stemmer, Nathan Geething
Abstract: The invention relates to a pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim 1 in combination with at least one second therapeutic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Type:
Application
Filed:
January 18, 2008
Publication date:
December 16, 2010
Applicants:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH, AJINOMOTO CO., INC.
Inventors:
Sabine Pinnetti, Ruediger Streicher, Leo Thomas, Klaus Dugi
Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
Type:
Application
Filed:
July 12, 2010
Publication date:
November 4, 2010
Applicant:
TRUBION PHARMACEUTICALS, INC.
Inventors:
JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, PETER AMSTRONG THOMPSON
Abstract: The invention provides composition and therapeutic, methods for modulating homeostatic pathways that are useful in treatment, and prevention of diabetes, diabetes associated disorders, metabolic disorders and cancer.
Type:
Application
Filed:
May 2, 2008
Publication date:
October 28, 2010
Inventors:
Stanley J. Korsmeyer, Susan R. Korsmeyer, Nika N. Danial, Loren D. Walensky, Gregory Bird
Abstract: The present invention is directed to peptide analogues of Exendin-3 and Exendin-4 and pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions containing said analogues and/or pharmaceutically-acceptable salts thereof.
Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
Type:
Application
Filed:
February 3, 2010
Publication date:
September 23, 2010
Inventors:
Volker Schellenberger, Joshua Silverman, Chia-wel Wang, Benjamin Spink, Willem P. Stemmer, Nathan C. Geething, Wayne To, Jeffrey L. Cleland